DBV Technologies (DBVT) Projected to Post Earnings on Thursday

DBV Technologies (NASDAQ:DBVT) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $1.08 million for the quarter.

DBV Technologies Stock Up 8.6 %

NASDAQ DBVT opened at $4.30 on Wednesday. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.09. The company has a market capitalization of $88.45 million, a PE ratio of -0.96 and a beta of 0.67. The firm’s 50 day moving average is $4.15 and its 200-day moving average is $3.81.

Wall Street Analyst Weigh In

DBVT has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of DBV Technologies in a report on Wednesday, February 26th. They issued a “hold” rating on the stock. JMP Securities reissued a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.